

6. Literaturverzeichnis

1. Statistisches Bundesamt Deutschland (http://www.destatis.de/themen/d/thm_gesundheit.php)
2. Chazov EL, Matveeva LS, Mazaev AV, et al. Intracoronary administration of fibrinolysis in acute myocardial infarction. *Ter. Arkh.* 1976; 48(4): 8 – 19
3. Rentrop P, Blanke H, Köstering H, et al. Intrakoronare Streptokinase-Applikation bei akutem Infarkt und instabiler Angina pectoris. *Dtsch. Med. Wschr.* 1980; 105(7): 221 – 228
4. Schröder R, Biamino GV, von Leitner ER, et al. Intravenous short-term infusion of streptokinase in acute myocardial infarction. *Circulation* 1982; 67:536 – 48
5. Neuhaus KL, Tebbe U, Sauer G, et al. High dose streptokinaseinfusion in acute myocardial infarction. *Clin Cardiol* 1983; 6(9): 426 – 434
6. Neuhaus KL, Köstering H, Tebbe U, et al. Intravenöse Kurzzeit-Streptokinase-Therapie beim frischen Myokardinfarkt. *Z Kardiol* 1981; 70: 791 – 796
7. Schröder R, Biamino GV, von Leitner ER, et al. Systemische Thrombolyse bei Streptokinase-Kurzzeitinfusion bei akutem Myokardinfarkt. *Z. Kardiologie* 1982; 71(11): 709 – 718
8. Yusuf S, Collins R, Peto R, Furberg C, et al. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. *Eur Heart J* 1985; 6: 556 – 585
9. ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction: mortality, morbidity and infarct size at 21 days. *N Engl J Med* 1986; 314: 465 – 471
10. Serruys PW, Simoons ML, Suryapranata H, et al. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. *J Am Coll Cardiol* 1986 7(4): 729 – 742
11. White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. *N Engl J Med* 1987 317(14): 850 – 855
12. Sheehan FH, Doerr R, Schmidt WG, et al. Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival. *J Am Coll Cardiol* 1988; 12(2): 289 - 300

13. AIMS Trail Study Group. Long term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. *Lancet* 1990; 335(8687): 427-431
14. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. *Lancet* 1987; 2(8564): 871 – 874
15. Gruppo Italiano per lo studio della streptochi-nasi nell'infarto miocardico (GISSI). Effectiveness in intravenous thrombolytic treatment in acute myocardial infarction. *Lancet* 1986; 1(8478): 397 – 402
16. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. *N Engl J Med* 1993; 329(22): 1615 – 1622
17. GUSTO Angiographic Investigators. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl. J Med.* 1993; 329:673 – 682
18. ISIS-2 (Second international study of infarct survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,189 cases of suspected acute myocardial infarction: ISIS-2. *J Am Coll Cardiol* 1988; 12(6 Suppl A): 3A – 13A
19. ISIS-3 (Third international study of infarct survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. heparin alone among 41,299 cases of suspected acute myocardial infarction. *Lancet* 1992; 339(8796): 753 – 770
20. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction Phase II Trial. *N Engl. J Med.* 1989; 320(10): 618 – 627
21. The TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. Phase I results. *N Engl. J Med.* 1985; 312(14): 932 – 936
22. The PRIMI Study Group. Randomised double-blind trial of recombinant pro-urikinase against streptokinase in acute myocardial infarction. *Lancet* 1989; 1(8643): 863 – 868
23. Wilcox RG, von der Lippe G, Olssen CG, et al. Trial of tissue plasminogen activator (rt-PA) for mortality reduction in acute myocardial infarction: the Anglo-Scandinavian Study of Early Thrombolysis (ASSET). *Lancet* 1988; 2(8610): 525 – 30

24. Simoons ML, Serruys PW, van den Brand M, et al. Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. *J Am Coll Cardiol* 1986; 7(4): 717 – 728
25. EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de America del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. *Lancet* 1993; 342(8874): 767 – 772
26. LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. *Lancet* 1993; 342(8874): 759 – 766
27. Meyer J, Merx W, Schmitz H, et al. Percutaneous transluminal coronary angioplasty immediately after intracoronary streptolysis of transmural myocardial infarction. *Circulation* 1982; 66(5): 905 – 913
28. Hartzler GO, Rutherford BD, McConahay DR, et al. Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarction. *Am Heart J* 1983; 106(5 Pt1): 965 – 973
29. Ellis SG, O'Neill WW, Bates ER, et al. Coronary Angioplasty as primary therapy for acute myocardial infarction 6 to 48 hours after symptom onset: report of an initial experience. *J Am Coll Cardiol* 1989; 13(5): 1122 – 1126
30. Brodie BR, Weintraub RA, Stuckey TD, et al. Outcome of direct coronary angioplasty for acute myocardial infarction in candidates and non-candidates for thrombolytic therapy. *Am J Cardiol* 1991; 67(1): 7 – 12
31. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. *N Engl J Med* 1993; 328:673 – 679
32. Gibbons RJ, Holmes DR, Reeder GS, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. *N Engl J Med* 1993; 328(10): 685 – 691
33. Assali AR, Iakobishvili Z, Zafir N, et al. Characteristics and clinical outcomes of patients with cardiogenic shock complicating acute myocardial infarction treated by emergent coronary angioplasty. *Int J Cardiovasc Intervent* 2005; 7(4):193-8.
34. de Boer MJ, Hoorntje CA, Ottervanger JP, et al. Immediate Coronary angioplasty versus intravenous streptokinase in acute myocardial infarction: left ventricular ejection fraction, hospital mortality and reinfarction. *J Am Coll Card* 1994; 23(5): 1004 – 1008

35. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue-plasminogen-activator for acute myocardial infarction. *N Engl J Med* 1997; 336(23): 1621 – 1628
36. Stone GW, Grines CL. Is there a role for percutaneous transluminal coronary angioplasty without antecedent thrombolysis in the treatment of acute myocardial infarction? *Cardiol Rev* 1994; 2:98 – 111
37. Brodie BR, Stone GW, Morice MC, et al. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). *Am J Cardiol* 2001; 88:1085 – 1090
38. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet* 2003; 361:13-20
39. Menon V, Fincke R. Cardiogenic shock: a summary of the randomized SHOCK trial. *Congest Heart Fail* 2003; 9(1): 35-9.
40. Hands ME, Rutherford JD, Muller JE, et al. The inhospital development of cardiogenic shock after acute myocardial infarction: Incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group. *J Am Coll Cardiol* 1989; 14(1): 40 – 48
41. Lee L, Erbel R, Brown TM, et al. Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long term survival. *J Am Coll Cardiol* 1991; 17(3): 599 – 603
42. Lee L, Bates ER, Pitt B, et al. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. *Circulation* 1988; 78(6): 1345 – 51
43. Kloner R. Does reperfusion injury exist in humans? *J Am Coll Card* 1993; 21:537 – 545
Braunwald E, Kloner R. Myocardial reperfusion: a double-edged sword? *J Clin Invest* 1985; 76(5): 1713-9
44. Hearse DJ, Bolli R. Reperfusion induced injury: manifestations, mechanisms, and clinical relevance. *Cardiovasc Res* 1992; 26(2): 101-8
45. Braunwald E, Kloner R. Myocardial reperfusion: a double-edged sword? *J Clin Invest* 1985; 76(5): 1713-9
46. Farb A, Kolodgie FD, Jenkins M, et al. Myocardial infarct extension during reperfusion after coronary artery occlusion: pathologic evidence. *J Am Coll Cardiol* 1993; 21:1245 – 1253

47. Sommers HM, Jennings RB. Experimental acute myocardial infarction. Histologic and histochemical studies of occlusion of a coronary artery. *Lab Invest* 1964; 13:1491 – 1503
48. Ambrosio G, Tritto I. Reperfusion injury: Experimental evidence and clinical implications. *Am Heart J* 1999; 138(2 Pt 2): S69 – S75
49. Mallory GK, White PD, Saldeco-Salgar J. The speed of healing of myocardial infarction. A study of the pathologic anatomy in seventy-two cases. *Am Heart J* 1939; 18:647 – 671
50. Jolly SR, Kane WJ, Hook BG, et al. Reduction of myocardial infarct size by neutrophil depletion: effect of duration of occlusion. *Am Heart J* 1986; 112(4): 682 – 690
51. Litt MR, Jeremy RW, Weisman HF, et al. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. *Circulation* 1989; 80(6): 1816 – 1827
52. Mullane KM, Read N, Salmon JA, et al. Role of leukocytes in acute myocardial infarction in anesthetized dogs: relationship to myocardial salvage by antiinflammatory drugs. *J Pharmacol Exp Ther.* 1984; 228(2): 510 – 522
53. Nobis U, Pries AR, Cokelet GR, et al. Radial distribution of white cells during blood flow in small tubes. *Microvasc Res* 1985; 29(3): 295 – 304
54. Ley K, Tedder TF. Leukocyte interactions with vascular endothelium: new insights into selectin-mediated attachment and rolling. *J Immunol* 1995; 155(2): 525 – 528
55. Ley K, Bullard DC, Arbones ML, et al. Sequential contribution of L- and P-selectin to leukocyte rolling in vivo. *J Exp Med* 1995; 181(2): 669 – 675
56. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. *Cell* 1994; 76(2): 301 – 314
57. Dore M, Korthuis RJ, Granger DN, et al. P-selectin mediates spontaneous leukocyte rolling in vivo. *Blood* 1993; 82(4): 1308 – 1316
58. Olofsson, AM, Arfors K-E, Ramezani L, et al. E-selectin mediates leukocyte rolling in interleukin-1-treated rabbit mesentery venules. *Blood* 1994; 84(8): 2749 – 2758
59. Kunkel EJ, Jung U, Bullard DC, et al. Absence of trauma induced leukocyte rolling in mice deficient in both P-selectin and intercellular adhesion molecule-1. *J Exp Med* 1996; 183(1): 57 – 65
60. Kishimoto TK, Jutila MA, Berg EL, et al. Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. *Science* 1989; 245(4923): 1238 – 1241

61. Ley K. Molecular mechanisms of leukocyte recruitment in the inflammatory process. *Cardiovasc Res* 1996; 32:733 – 742
62. Diamond MS, Staunton DE, Marlin SD, et al. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. *Cell* 1991; 65(6): 961 – 971
63. Dustin ML, Springer TA. Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of the three mechanisms for lymphocyte adhesion to cultured endothelial cells. *J Cell Biol* 1988; 107(1): 321 – 331
64. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. *Cell* 1990; 60(4): 577 – 84
65. Vaporciyan AA, DeLisser HM, Yan H-C, et al. Involvement of platelet-endothelial-adhesion-molecule-1 in neutrophil recruitment in vivo. *Science* 1993; 262(5139): 1580 – 1582
66. Neuhaus KL, von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patience study (TAPS) *J Am Coll Cardiol* 1992; 19:885 – 891
67. Tanswell P, Tebbe U, Neuhaus KL, et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. *J Am Coll Cardiol* 1992; 19:1071 – 1075
68. Ma X, Lefer DJ, Lefer AM, et al. Coronary endothelial and cardiac protective effects of monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion. *Circulation* 1992; 86: 937 – 946
69. Schleiffenbaum B, Spertini O, Tedder TF. Soluble L-Selectin is present in human plasma at high levels and retains functional activity. *J Cell Biol* 1992; 119: 229 – 238
70. Entman M, Smith CW. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. *Cardiovasc Res* 1994; 28:1301 – 1311
71. Sakurai S, Inoue A, Koh CS, et al. Soluble forms of selectins in blood of patients with acute myocardial infarction and coronary intervention. *Vasc Med* 1997; 2:163 – 168
72. Pudil R, Pidrman V, Krejsek J, et al. Cytokines and adhesion molecules in the course of acute myocardial infarction. *Clin Chim Acta* 1999; 280 (1-2): 127 – 134

73. Li YH, Teng JK, Tsai WC, et al. Elevation of soluble adhesion molecules is associated with the severity of myocardial damage in the acute myocardial infarction.
Am J Cardiol 1999; 80(9): 1218 – 1221
74. Zeitler H, Ko Y, Zimmermann C, et al. Elevated serum concentrations of soluble adhesion molecules in coronary artery disease and acute myocardial infarction.
Eur J Med Res 1997; 2(9): 389 – 394
75. Printseva OY, Peclo MM, Gown AM. Various cell types in human atherosclerotic lesions express ICAM-1. Further immunocytochemical and immunochemical studies employing monoclonal antibody 10F3. *Am J Path* 1992; 140(4): 889 – 896
76. Guray U, Erbay AR, Guray Y, et al. Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis. *Int J Cardiol* 2004; 96(2): 235-40
77. Tomoda H, Aoki N. Plasma soluble P-Selectin in acute myocardial infarction: effects of coronary recanalization therapy. *Angiology* 1998; 49(10): 807 – 813
78. Stenberg PE, McEver RP, Shuman MA, et al. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation.
J Cell Biol 1985; 101(3): 880 – 86
79. McEver RP, Beckstead JH, Moore KL, Marshall, et al. GMP-140, a platelet a-granule membrane protein, is also synthesized by vascular endothelial cells and localized in Weibel-Palade bodies. *J Clin Invest* 1989; 84(1): 92 – 99
80. Weyrich AS, Ma X, Lefer DJ, et al. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury.
J Clin Invest 1993; 91(6): 2620 – 2629
81. Johnston GI, Bliss GA, Newman PJ, et al. Structure of the human gene encoding granule protein-140, a member of the selectin family of adhesion receptors for leukocytes.
J Biol Chem 1990; 265(34): 21381 – 21385
82. Foxall C, Watson SR, Dowbenko D, et al. The three members of the selectin receptor family recognise a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide.
J Cell Biol 1992; 117(4): 895 – 902
83. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules.
Blood 1994; 84(7): 2068 – 2101

84. Silver MJ, Sutton JM, Hook S, et al. Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in electrolytic canine coronary artery model. *Circulation* 1995; 92(2): 492 – 499
85. Gamble JR, Skinner MP, Berndt MC, et al. Prevention of activated neutrophil adhesion to endothelium by soluble adhesion protein GMP-140. *Science* 1990; 249(4967): 414 – 417
86. Lorant DE, Topham MK, Whatley RE, et al. Inflammatory roles of P-selectin. *J Clin Invest* 1993; 92(2): 559 – 570
87. Lefer AM, Weyrich AS, Buerke M. Role of selectins, a new family of adhesion molecules, in ischemia-reperfusion injury. *Cardiovasc Res* 1994; 28(3): 289 – 294
88. Ikeda H, Takajo Y, Ichiki K, et al. Increased soluble form of P-selectin in patients with unstable angina. *Circulation* 1995; 92:1693 – 1696
89. Kaikita K, Ogawa H, Yasue H, et al. Soluble P-selectin is released into the coronary circulation after coronary spasm. *Circulation* 1995; 92:1726 – 1730
90. Atalar E, Aytemir K, Haznedaroglu I, et al. Increased plasma levels of soluble selectins in patients with unstable angina. *Int J Cardiol* 2001; 78:69 – 73
91. Montrucchio G, Lupia E, De Martino A, et al. Plasmin promotes an endothelium-dependent adhesion of neutrophils. Involvement of platelet activating factor and P-selectin. *Circulation* 1996; 93(12): 2152 – 2160
92. Kayikcioglu M, Can L, Mete-Erdem N, et al. Soluble P-Selectin and the success of thrombolysis in acute myocardial infarction. *In J Cardiol* 2001; 79:223 – 229
93. Gamble JR, Skinner MP, Berndt MC, et al. Prevention of activated neutrophil adhesion to endothelium. *Science* 1990; 249(4967): 414 – 417
94. Bevilacqua MP, Stengelin S, Gimbrone MA Jr, et al. Endothelial-leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. *Science* 1989; 243(4895): 1160 – 1165
95. Bevilacqua MP, Nelson RM. Selectins. *J Clin Invest* 1993; 91(2): 379 – 387
96. Kurz RW, Graf B, Gremmel F, et al. Increased serum concentrations of adhesion molecules after coronary angioplasty. *Clin Sci (Colch)* 1994; 87:627 – 633
97. Pellegatta F, Pizzetti G, Lu Y, et al. Soluble E-selectin and intercellular adhesion molecule-1 plasma levels increase during acute myocardial infarction. *J Cardiovasc Pharmacol* 1997; 30(4): 455 – 460

98. Weyrich A, Buerke M, Albertine KH, et al. Time course of coronary vascular endothelial adhesion molecule expression during reperfusion of the ischemic feline myocardium. *J Leukoc Biol* 1995; 57(1): 45 – 55
99. Siminiak T, Dye JF, Egdell RM, et al. The release of soluble adhesion molecules ICAM-1 and E-selectin after acute myocardial infarction and following coronary angioplasty. *Int J Cardiol* 1997; 61(2): 113-118
100. Yoshida N, Granger DN, Anderson DC, et al. Anoxia/reoxygenation-induced neutrophil adherence to cultured endothelial cells. *Am J Physiol* 1992; 262(6 Pt 2): H1891 – H1898
101. Gurbel PA, Serebruany VL. Soluble vascular cell adhesion molecule-1 and E-selectin in patients with acute myocardial infarction treated with thrombolytic agents. *Am J Cardiol* 1998; 81:772 – 775
102. Squadrito F, Saitta A, Altavilla D, et al. Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction. *Inflamm Res* 1996; 45(1): 14 – 19
103. Shyu KG, Chang H, Lin CC, et al. Circulating intercellular molecule-1 and E-selectin in patients with acute coronary syndrome. *Chest* 1996; 109(6): 1627-1630
104. Wallen NH, Held C, Rehnqvist N, et al. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. *Eur Heart J* 1999; 20(14): 1039 – 1043
105. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. *Circulation* 2001; 104(12): 1336 – 1342
106. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk on Communities (ARIC) Study. *Circulation* 1997; 96(12): 4219 – 4225
107. Pizcueta P, Lusinskas FW. Monoclonal antibody blockade of L-selectin inhibits mononuclear leukocyte recruitment to inflammatory sites in vivo. *Am J Pathol* 1994; 145(2): 461 – 469
108. Ley K, Gaehtgens P, Fennie C, et al. Lectin-like cell adhesion molecule-1 mediates leukocyte rolling in mesenteric venules in vivo. *Blood* 1991; 77(12): 2553 – 2555

109. Von Andrian UH, Hasslen SR, Nelson RD, et al. A central role for microvillous receptor presentation in leukocyte adhesion under flow. *Cell* 1995; 82(6): 989 – 999
110. Bargatze RF, Kurk S, Butcher EC, et al. Neutrophils roll on adherent neutrophils bound on cytokine-induced endothelial cells via L-selectin on the rolling cells. *J Exp Med* 1994; 180(5): 1785 – 1792
111. Griffin JD, Spertini O, Ernst TJ, et al. GM-CSF and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. *J Immunol* 1990; 145(2): 576 – 584
112. Spertini O, Schleiffenbaum B, White-Owin C, et al. ELISA for quantification of L-selectin shed from leukocytes in vivo. *J Immun Methods* 1992; 156(1): 115 – 123
113. Donnelly SC, Haslett C, Dransfield I, et al. Role of selectins in development of adult respiratory distress syndrome. *Lancet* 1984; 344: 215 – 219
114. Muller JC, Buhner C, Kiening KL, et al. Decreased soluble adhesion molecule L-selectin plasma concentrations after major trauma. *J Trauma* 1998; 45:705 – 708
115. Kerner T, Ahlers O, Spielmann S, et al. L-selectin in trauma patients: a marker for organ dysfunction and outcome? *Eur J Clin Invest* 1999; 29:1077 – 1086
116. Hought WH, Mansour M, Rothlein R, et al. Alterations in circulating intercellular adhesion molecule-1 and L-selectin: further evidence for chronic inflammation in ischemic heart disease. *Am Heart J* 1996; 132:1 – 8
117. Bereta J, Bereta M, Cohen S, et al. Regulation of VCAM-1 expression and involvement in cell adhesion to murine microvascular endothelium. *J Cell Immunol* 1993; 147(2): 313 – 330
118. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. *Cell* 1990; 60(4): 577 – 584
119. Pigott R, Dillon LP, Hemingway IH, et al. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. *Biochem Biophys Res Comm* 1992; 187(2): 584 – 589
120. Mulvihill N, Foley B, Ghaisas N, et al. Early temporal expression of soluble cellular adhesion molecules in patients with unstable angina and subendocardial myocardial infarction. *Am J Cardiol* 1999; 83: 1265 – 1267

121. Buemi M, Allegra A, Aloisi C, et al. Cold pressor test raises serum concentrations of ICAM-1, VCAM-1, and E-selectin in normotensive and hypertensive patients. *Hypertension* 1997; 30: 845 – 847
122. Semaan HB, Gurbel PA, Anderson JL, et al. Soluble VCAM-1 and E-selectin, but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease. *Cardiology* 2000; 93:7 – 10
123. Meerschaert J, Furie MB. Monocytes use either CD11/CD18 or VLA-4 to migrate across endothelium in vitro. *J Immunol* 1994; 152(4): 1915 – 1926
124. Ebisawa M, Bochner BS, Georas SN, et al. Eosinophil transendothelial migration induced by cytokines. I. Role of endothelial and eosinophil adhesion molecules in IL-1 beta-induced transendothelial migration. *J Immunol* 1992; 149(12): 4021 – 4028
125. Watt SM, Gschmeissner SE, Bates PA. PECAM-1: its expression and function as a cell adhesion molecule on hemopoietic and endothelial cells. *Leuk Lymphoma* 1995; 17(3-4): 229 – 244
126. Gumina RJ, el Schultz J, Yao Z, Kenny D, et al. Antibody to platelet/endothelial cell adhesion molecule-1 reduces myocardial infarct size in a rat model of ischemia-reperfusion injury. *Circulation* 1996; 94(12): 3327 – 3333
127. Goldberger A, Middleton KA, Oliver JA, et al. Biosynthesis and processing of the cell adhesion molecule PECAM-1 induces production of a soluble form. *J Biol Chem* 1994; 269(25): 17183 – 17191
128. DeLisser HM, Newman PJ, Albelda SM. Molecular and functional aspects of PECAM-1/CD31. *Immunol Today* 1994; 15(10): 490 – 495
129. Muller WA. The role of PECAM-1 (CD31) in leukocyte emigration: studies in vitro and in vivo. *J Leukoc Biol* 1995; 57(4): 523 – 528
130. Murohara T, Delyani JA, Albelda SM, et al. Blockade of platelet endothelial cell adhesion molecule-1 protects against myocardial ischemia and reperfusion injury. *J Immunol* 1996; 156(9): 3550 – 3557
131. Serebruany VL, Gurbel PA. Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. *Arterioscler Thromb Vasc Biol* 1999; 19: 153 – 158

132. Soeki T, Tamura Y, Shinohara H, et al. Increased soluble platelet/endothelial cell adhesion molecule-1 in the early stages of acute coronary syndromes.
Int J Cardiol 2003 90(2-3): 261-8
133. Serebruany VL, Murugesan SR, Pothula A, et al. Soluble PECAM-1, but not P-selectin, nor osteonectin identify acute myocardial infarction in patients presenting with chest pain.
Cardiology 1999; 91: 50 – 55
134. Dustin ML, Rothlein R, Bhan AK, et al. Induction by Il-1 and interferon α : tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1).
J Immunol 1986; 137(1): 245 – 254
135. Hogg N, Bates PA, Harvey J. Structure and function of intercellular adhesion molecule-1.
Chem Immunol 1991; 50: 98 – 115
136. Diamond MS, Staunton DE, de Fougerolles AR, et al. ICAM-1 (CD54): A counter-receptor for Mac-1 (CD11b/C18). J Cell Biol 1990; 111(6 Pt 2): 3129 – 3139
137. Lefer AM. Role of the β_2 -Integrins and immunoglobulin superfamily members in myocardial ischemia-reperfusion. Ann Thorac Surg 1999; 68(5): 1920 – 1923
138. Miwa K, Igawa A, Inoue H. Soluble E-selectin, ICAM-1 and VCAM-1 levels in systemic and coronary circulation in patients with variant angina. Cardiovasc Res 1997; 36:37 – 44
139. Kusterer K, Bojunga J, Enghofer M, Heidenthal et al. Soluble ICAM-1 reduces leukocyte adhesion to vascular endothelium in ischemia-reperfusion injury in mice.
Am J Physiol 1998; 275(2 Pt 1): G377 – G380
140. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. Plasma concentration of soluble intercellular adhesion molecule-1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351(9096): 88 – 92
141. Luc G, Arveiler D, Evans A, et al; PRIME Study Group. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis 2003; 170(1): 169-76.
142. Couffinhal T, Duplaa C, Moreau C, et al. Regulation of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in human vascular smooth muscle cells.
Circ Res 1994; 74(2): 225 – 234
143. Fuster V. Lewis A, Conner Memorial Lecture Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90(4): 2126 – 2146

144. Kaikita K, Ogawa H, Yasue H, et al. Increased plasma soluble intercellular adhesion molecule-1 levels in patients with acute myocardial infarction. *Jpn Circ J* 1997; 61(9): 741 – 748
145. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. *Am J Cardiol* 1995; 75(6): 12B – 17B
146. Zhang RL, Zhang ZG, Chopp M, et al. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. *Stroke* 1999; 30(3): 624 – 629
147. Gurbel P, O'Connor CM, Dalesandro MR, et al. Relation of soluble and platelet P-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy. *Am J Cardiol* 2001; 87(6): 774 – 777, A7
148. Rallidis LS, Gika HI, Zolindaki MG, et al. Usefulness of elevated levels of soluble vascular cell adhesion molecule-1 in predicting in-hospital prognosis in patients with unstable angina pectoris. *Am J Cardiol* 2003; 92(10): 1195-7